WASHINGTON (CN) - The Food and Drug Administration is allowing more time for comment on a consumer distraction study, regarding a proposed rule to establish standards for whether the side effects and contraindications of an advertised prescription is presented in a clear, conspicuous, and neutral manner on television or radio.
The rule was proposed March 29, 2010, and on Jan. 27, 2012, the FDA announced that it had added a study to the docket entitled "Experimental Evaluation of the Impact of Distraction on Consumer Understanding of Risk and Benefit Information in Direct-to-Consumer Prescription Drug Television Advertisements" and the public was given until Feb. 27, 2012, to comment on this study as it regards the proposed standards.
Electronic or written comments are due by by April 9.
Click the document icon for this regulation and others.
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026